Lymphocyte Activation Gene 3 Protein

A CD4-related protein with high affinity cell surface binding to MHC class II. It functions in downregulation of T cell proliferation following binding to MHC class II molecules.

Also Known As:

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 10/05/2023 - "Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. " 10/15/2022 - "Lymphocyte activation gene 3 protein (LAG3; CD223) is an inhibitory receptor that is highly upregulated on exhausted T cells in tumors and chronic viral infection. "
2.	Virus Diseases (Viral Diseases) 10/15/2022 - "Lymphocyte activation gene 3 protein (LAG3; CD223) is an inhibitory receptor that is highly upregulated on exhausted T cells in tumors and chronic viral infection. "
3.	Melanoma (Melanoma, Malignant) 11/01/2023 - "Relatlimab is a human anti-lymphocyte activation gene 3 protein antibody approved for the treatment of metastatic or unresectable melanoma in combination with nivolumab, an existing programmed cell death protein 1 inhibitor. "
4.	Carcinoma (Carcinomatosis) 05/13/2023 - "Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma."

Related Drugs and Biologics

1.	Immune Checkpoint Inhibitors
2.	Nivolumab
3.	relatlimab